Neuronetics Engages in Innovative Healthcare Conference Talks
MALVERN, Pa. — Neuronetics, Inc. (NASDAQ: STIM), a pioneer in medical technology, is set to share insights at the Piper Sandler 37th Annual Healthcare Conference. The event, taking place on a future date, will showcase the company’s commitment to improving patient care through advanced neurohealth therapies.
Leading the Way in Neurohealth
As a standout entity in neuroscience, Neuronetics believes in the critical importance of mental wellness, akin to physical health. The company is committed to broadening access to innovative treatment options, particularly through its flagship offering, the NeuroStar Advanced Therapy. This non-drug approach stands out in its ability to benefit individuals grappling with neurohealth disorders, particularly for those who have not found relief through typical medications.
Innovative Treatments Available
The NeuroStar Advanced Therapy System provides noninvasive treatment modalities that significantly enhance the quality of life for many patients. With over 7.4 million treatments delivered, it has become the leading transcranial magnetic stimulation (TMS) therapy for major depressive disorder (MDD) in adults and is supported by extensive clinical data—making it a trusted choice for healthcare providers.
Greenbrook Treatment Centers and Their Impact
Beyond just selling the NeuroStar therapy system, Neuronetics operates Greenbrook TMS Inc. facilities across the nation. These centers not only administer the NeuroStar Advanced Therapy for MDD but also provide treatment involving SPRAVATO® (esketamine) Nasal Spray. This medicine helps treat treatment-resistant depression and is a significant tool for addressing acute depressive symptoms, leading to thousands of successful patient outcomes.
The Importance of FDA Clearance
The NeuroStar Advanced Therapy is proudly cleared by the U.S. Food and Drug Administration for various applications. These include not only treating adults experiencing MDD but also assisting those with obsessive-compulsive disorder and anxiety symptoms. For younger patients aged 15 to 21, it serves as a first-line adjunct therapy for MDD, underscoring the company’s dedication to providing age-appropriate medical solutions.
Contact Information for Investors
For those interested in learning more about Neuronetics and engaging with its stock offerings, investor inquiries can be directed to:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Relations
For media inquiries, please reach out to:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
Frequently Asked Questions
What is Neuronetics known for?
Neuronetics is known for its innovative treatments for mental health, particularly through the NeuroStar Advanced Therapy.
What major events is Neuronetics participating in?
Neuronetics is participating in the Piper Sandler 37th Annual Healthcare Conference to discuss new developments in their therapies.
How many treatments has NeuroStar delivered?
Neuronetics has delivered over 7.4 million NeuroStar treatments to date.
What is Greenbrook TMS, Inc.?
Greenbrook TMS, Inc. operates treatment centers providing NeuroStar Advanced Therapy across the United States.
How can I contact Neuronetics for more information?
Interested parties can contact Neuronetics through their investor relations email at ir@neuronetics.com.
